Literature DB >> 28200098

Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics.

Timothy M Block1, Stephen Locarnini2, Brian J McMahon3, Barbara Rehermann4, Marion G Peters5.   

Abstract

New hepatitis B virus (HBV) therapies are expected to have breakthrough benefit for patients. HBV functional cure is sustained hepatitis B surface antigen loss and anti-HBs gain, with normalization of serum aminotransferases off therapy. Virologic or complete cure additionally includes loss of HBV covalently closed circular DNA. Currently available endpoints of therapy are inadequate to evaluate the efficacy of many of the new therapeutics. Therefore, either new ways of using the existing virologic endpoints and laboratory values or entirely new biomarkers are needed. In this review, we discuss the currently used endpoints, potential new endpoints, as well as what new markers are needed to assess the ability of HBV therapeutics to achieve functional and virologic cure in various phases of HBV infection. In addition, we discuss how patient selection from differing phases of HBV impacts the choice of HBV drug(s) needed to achieve cure.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  immunology; pathology; therapeutics; virology; markers

Mesh：

Substances：

Year:  2017        PMID： 28200098      PMCID： PMC5848252          DOI： 10.1093/cid/cix129

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  40 in total

1.  Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound.

Authors:  Jie Wang; Tao Shen; Xiangbo Huang; G Renuka Kumar; Xiangmei Chen; Zhenzhen Zeng; Ruiyang Zhang; Ran Chen; Tong Li; Tianying Zhang; Quan Yuan; Pao-Chen Li; Qi Huang; Richard Colonno; Jidong Jia; Jinlin Hou; Malcolm A McCrae; Zhiliang Gao; Hong Ren; Ningshao Xia; Hui Zhuang; Fengmin Lu
Journal:  J Hepatol       Date:  2016-05-28       Impact factor: 25.083

Review 2.  Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report.

Authors:  Henry Lik-Yuen Chan; Alex Thompson; Michelle Martinot-Peignoux; Teerha Piratvisuth; Markus Cornberg; Maurizia Rossana Brunetto; Hans L Tillmann; Jia-Horng Kao; Ji-Dong Jia; Heiner Wedemeyer; Stephen Locarnini; Harry L A Janssen; Patrick Marcellin
Journal:  J Hepatol       Date:  2011-06-28       Impact factor: 25.083

3.  Hepatitis B Virus--Specific and Global T-Cell Dysfunction in Chronic Hepatitis B.

Authors:  Jang-June Park; David K Wong; Abdus S Wahed; William M Lee; Jordan J Feld; Norah Terrault; Mandana Khalili; Richard K Sterling; Kris V Kowdley; Natalie Bzowej; Daryl T Lau; W Ray Kim; Coleman Smith; Robert L Carithers; Keith W Torrey; James W Keith; Danielle L Levine; Daniel Traum; Suzanne Ho; Mary E Valiga; Geoffrey S Johnson; Edward Doo; Anna S F Lok; Kyong-Mi Chang
Journal:  Gastroenterology       Date:  2015-12-10       Impact factor: 22.682

4.  A novel baseline hepatitis B virus sequencing-based strategy for predicting adefovir antiviral response.

Authors:  Yu-Wei Wang; Xuefeng Shan; Yao Huang; Haijun Deng; Wen-Xiang Huang; Da-Zhi Zhang; Juan Chen; Ni Tang; You-Lan Shan; Jin-Jun Guo; Ailong Huang
Journal:  Infect Genet Evol       Date:  2015-05-14       Impact factor: 3.342

5.  A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.

Authors:  Hashem B El-Serag; Fasiha Kanwal; Jessica A Davila; Jennifer Kramer; Peter Richardson
Journal:  Gastroenterology       Date:  2014-01-23       Impact factor: 22.682

6.  Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis.

Authors:  Mireen Friedrich-Rust; William Rosenberg; Julie Parkes; Eva Herrmann; Stefan Zeuzem; Christoph Sarrazin
Journal:  BMC Gastroenterol       Date:  2010-09-09       Impact factor: 3.067

7.  AASLD guidelines for treatment of chronic hepatitis B.

Authors:  Norah A Terrault; Natalie H Bzowej; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; M Hassan Murad
Journal:  Hepatology       Date:  2015-11-13       Impact factor: 17.425

8.  Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease.

Authors:  Quan Yuan; Liu-Wei Song; Daniela Cavallone; Francesco Moriconi; Beatrice Cherubini; Piero Colombatto; Filippo Oliveri; Barbara Agata Coco; Gabriele Ricco; Ferruccio Bonino; James Wai Kuo Shih; Ning-Shao Xia; Maurizia Rossana Brunetto
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

Review 9.  Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections.

Authors:  Barbara Rehermann; Antonio Bertoletti
Journal:  Hepatology       Date:  2015-02       Impact factor: 17.425

10.  Antibody responses during hepatitis B viral infection.

Authors:  Stanca M Ciupe; Ruy M Ribeiro; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2014-07-31       Impact factor: 4.475
View more
  11 in total

Review 1.  Humoral immunity, the underestimated player in hepatitis B.

Authors:  Shuye Zhang; Juanjuan Zhao; Zheng Zhang
Journal:  Cell Mol Immunol       Date:  2017-12-11       Impact factor: 11.530

2.  New Direct-Acting Antiviral Agents and Immunomodulators for Hepatitis B Virus Infection.

Authors:  Marion G Peters; Stephen Locarnini
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-06

3.  Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

Authors:  Carla S Coffin; Scott K Fung; Fernando Alvarez; Curtis L Cooper; Karen E Doucette; Claire Fournier; Erin Kelly; Hin Hin Ko; Mang M Ma; Steven R Martin; Carla Osiowy; Alnoor Ramji; Edward Tam; Jean Pierre Villeneuve
Journal:  Can Liver J       Date:  2018-12-25

4.  Modeling explains prolonged SARS-CoV-2 nasal shedding relative to lung shedding in remdesivir-treated rhesus macaques.

Authors:  Ashish Goyal; Elizabeth R Duke; E Fabian Cardozo-Ojeda; Joshua T Schiffer
Journal:  iScience       Date:  2022-05-25

5.  Expression Level of Small Envelope Protein in Addition to Sequence Divergence inside Its Major Hydrophilic Region Contributes to More Efficient Surface Antigen Secretion by Hepatitis B Virus Subgenotype D2 than Subgenotype A2.

Authors:  Qianru Wang; Shuwen Fu; Jing Zhang; Quan Yuan; Jisu Li; Ningshao Xia; Yu-Mei Wen; Yongxiang Wang; Shuping Tong
Journal:  Viruses       Date:  2020-09-01       Impact factor: 5.048

6.  Moving Fast Toward Hepatitis B Virus Elimination.

Authors:  Leda Bassit; Suzane Kioko Ono; Raymond F Schinazi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 7.  The Lived Experience of Chronic Hepatitis B: A Broader View of Its Impacts and Why We Need a Cure.

Authors:  Thomas Tu; Joan M Block; Su Wang; Chari Cohen; Mark W Douglas
Journal:  Viruses       Date:  2020-05-07       Impact factor: 5.048

Review 8.  Liver sampling: a vital window into HBV pathogenesis on the path to functional cure.

Authors:  Upkar S Gill; Laura J Pallett; Patrick T F Kennedy; Mala K Maini
Journal:  Gut       Date:  2018-01-13       Impact factor: 23.059

9.  Hepatitis B and HIV-1 2019 IAS Cure Forum: lessons and benefits from interdisciplinary research.

Authors:  M Paximadis; S Perez Patrigeon; R Rajasuriar; R Tatoud; E Scully; P Arbuthnot
Journal:  J Virus Erad       Date:  2019-11-04

Review 10.  Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy.

Authors:  Eriko Ohsaki; Yadarat Suwanmanee; Keiji Ueda
Journal:  Viruses       Date:  2021-08-26       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.